logo
Share SHARE
FONT-SIZE Plus   Neg

European Commission Gives Green Light To Bayer HealthCare's Flexyess

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said the European Commission has issued its go ahead for the approval of the company's subgroup Bayer HealthCare's new low-dose combined oral contraceptive Flexyess. Based on the European Commission's positive decision, the Health Authorities of the EU Member States will grant national approvals in the coming weeks.

Flexyess will be the first low-dose combined oral contraceptive approved in the EU member states for a flexible extended regimen, offering women the option of 'personal period planning', meaning they can choose both the number and timing of their periods according to their needs.

Dr. Flemming Ornskov, chief marketing officer at Bayer HealthCare's Pharmaceuticals division, said, "Once Flexyess is launched, women will have the convenience and flexibility to influence the timing of their periods according to their individual needs."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Justice Department has initiated a probe to find out if airlines are colluding to limit seating capacity in order to benefit from higher airfares. Saudi Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud has pledged to give away his entire wealth amounting to $32 billion for charity. He said the fund will be utilized for cultural understanding, develop communities, empower women, enable youth, provide vital disaster relief and create a more tolerant and accepting world. Toyota accepted the resignation of its Chief Communications Officer Julie Hamp, following her arrest in Japan for allegedly mailing banned painkillers to her address in Japan from U.S.
comments powered by Disqus
Follow RTT